The ClinicianThe ClinicianКлиницист1818-83382412-8775Publishing House ABV Press3010.17650/1818-8338-2013-7-2-221-235LECTIONЛЕКЦИЯDIABETIC POLYNEUROPATHY: CURRENT APPROACHES TO DIAGNOSIS AND PATHOGENETIC THERAPYДиабетическая полиневропатия : современные подходы к диагностике и патогенетической терапииLevinO. S.ЛевинО. С.
Russian Federation

Department of Neurology

Кафедра неврологии

oslevin@mail.ruRussian Medical Academy of Postgraduate Education, Ministry of HealthГБОУ ДПО РМАПО Минздрава России150420137254631407201414072014Copyright ©; 2013, Levin O.S.Copyright ©; 2013, Левин О.С.2013Levin O.S.Левин О.С.https://creativecommons.org/licenses/by/4.0https://klinitsist.abvpress.ru/Klin/article/view/30

The paper considers the current views of the prevalence, clinical picture, approaches to the diagnosis and treatment of one of the most commonneurological complications of diabetes mellitus – diabetic polyneuropathy, and both its somatic and autonomous manifestations. Neuropathy ismost common in diabetic patients and its clinical forms reflect the severe course of diabetes mellitus and serve as an unfavorable prognostic signthat is associated with an approximately 5-fold increase in mortality. At the same time, the timely detection and adequate correction of the manifestations of neuropathy may substantially improve quality of life in the patients. The possibilities of pathogenetic therapy for diabetic polyneuropathy associated mainly with the use of benfotiamine and alpha-lipoic acid, as well as symptomatic therapy for its individual manifestationsare considered.

Рассмотрены современные представления о распространенности, клинической картине, подходах к диагностике и лечению одного из наиболее частых неврологических осложнений сахарного диабета – диабетической полиневропатии, как соматических, так и вегетативных ее проявлений. Развитие невропатии имеет высокую распространенность среди больных диабетом, а клинически выраженные ее формы отражают тяжелое течение сахарного диабета и служат неблагоприятным прогностическим признаком, сопряженным с увеличением смертности примерно в 5 раз. В то же время своевременное выявление и адекватная коррекция проявлений невропатии могут существенно улучшать качество жизни больных. Рассмотрены возможности патогенетической терапии диабетической полиневропатии, связанные с применением бенфотиамина и альфа-липоевой кислоты, а также симптоматической терапии ее отдельных проявлений.

diabetes mellituspolyneuropathybenfotiaminealpha-lipoic acidсахарный диабетполиневропатиябенфотиаминальфа-липоевая кислота1. Верткин А.Л., Ткачева О.Н., Подпругина Н.Г. и др. Диабетическая автономная нейропатия: диагностика и метаболическая нейропатия. Клин фармакол и тер 2004;(4):4–8.Верткин А.Л., Ткачева О.Н., Подпругина Н.Г. и др. Диабетическая автономная нейропатия: диагностика и метаболическая нейропатия. Клин фармакол и тер 2004;(4):4–8.2. American Diabetes Association. Diagnosis and classification of diabetes mellitus. DiabetesAmerican Diabetes Association. Diagnosis and classification of diabetes mellitus. DiabetesCare 2009;32(Suppl 1):S62–7.3. Левин О.С. Полиневропатия. М.: МИА, 2006.Левин О.С. Полиневропатия. М.: МИА, 2006.4. Boulton A.J., Vinik A.I., Arezzo J.C. et al. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care 2005;28(4):956–62.Boulton A.J., Vinik A.I., Arezzo J.C. et al. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care 2005;28(4):956–62.5. Dyck P.J., Karnes J.L., O’Brien P.C. et al. The Rochester Diabetic Neuropathy Study: reassessment of tests and criteria for diagnosis and staged severity. Neurology 1992;42(6):1164–70.Dyck P.J., Karnes J.L., O’Brien P.C. et al. The Rochester Diabetic Neuropathy Study: reassessment of tests and criteria for diagnosis and staged severity. Neurology 1992;42(6):1164–70.6. Vinik A.I., Mehrabyan A. Diabetic neuropathies. Med Clin North Am 2004;88(4):947–99.Vinik A.I., Mehrabyan A. Diabetic neuropathies. Med Clin North Am 2004;88(4):947–99.7. Boulton A., Tesfaye S. (eds.) Diabetic neuropathy. Oxford: Oxford Diabetes Library, 2009.Boulton A., Tesfaye S. (eds.) Diabetic neuropathy. Oxford: Oxford Diabetes Library, 2009.8. Строков И.А., Баринов А.Н. Клиника, патогенез и лечение болевого синдрома при диабетической полиневропатии. Неврол журн 2001;6(6):47–54.Строков И.А., Баринов А.Н. Клиника, патогенез и лечение болевого синдрома при диабетической полиневропатии. Неврол журн 2001;6(6):47–54.9. Trence D.L. Peripheral neuropathy in diabetes: is it diabetic neuropathy? Clin Diabetes 2002;20(2):103–4.Trence D.L. Peripheral neuropathy in diabetes: is it diabetic neuropathy? Clin Diabetes 2002;20(2):103–4.10. Ziegler D. Treatment of diabetic neuropathy and neuropathic pain. Diabetes Care 2008;31(Suppl 2):S255–21.Ziegler D. Treatment of diabetic neuropathy and neuropathic pain. Diabetes Care 2008;31(Suppl 2):S255–21.11. Dyck P.J., Thomas P.K. (eds.) Diabetic neuropathy. 2nd ed. Philadelphia: WB Saunders, 1999.Dyck P.J., Thomas P.K. (eds.) Diabetic neuropathy. 2nd ed. Philadelphia: WB Saunders, 1999.12. Stracke H., Gaus W., Achenbach U. et al. Benfotiamine in Diabetic Polyneuropathy (BENDIP): results of a randomised, double-blind, placebo-controlled clinical study. Exp Clin Endocrinol DiabetesStracke H., Gaus W., Achenbach U. et al. Benfotiamine in Diabetic Polyneuropathy (BENDIP): results of a randomised, double-blind, placebo-controlled clinical study. Exp Clin Endocrinol Diabetes2008;116(10):600–5.;116(10):600–5.13. Tesfaye S., Stevens L.K., Stephenson J.M. et al. Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: the EURODIAB IDDM Complications Study.Tesfaye S., Stevens L.K., Stephenson J.M. et al. Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: the EURODIAB IDDM Complications Study.Diabetologia 1996;39(11):1377–84.14. Gries F.A., Cameron N.E., Low P.A. (eds.) Textbook of diabetic neuropathy. Stuttgart: Thieme, 2003.Gries F.A., Cameron N.E., Low P.A. (eds.) Textbook of diabetic neuropathy. Stuttgart: Thieme, 2003.15. Kramer H.Н., Rolke R., Hecht M. et al. Follow-up of advanced diabetic neuropathy. J Neurol 2005;252(3):315–20.Kramer H.Н., Rolke R., Hecht M. et al. Follow-up of advanced diabetic neuropathy. J Neurol 2005;252(3):315–20.16. Штульман Д.Р., Левин О.С. Неврология. Справочник практического врача. М.: МЕДпресс-информ, 2008.Штульман Д.Р., Левин О.С. Неврология. Справочник практического врача. М.: МЕДпресс-информ, 2008.17. Dyck P.J. Diabetic radiculoplexus neuropathies. In: Noseworthy J.H. (ed.). NeurologicalDyck P.J. Diabetic radiculoplexus neuropathies. In: Noseworthy J.H. (ed.). Neurologicaltherapeutics: principles and practice. Martin Dunitz, 2003. Pp. 2007–10.18. Shaw J.E., Zimmet P.Z., Gries F.A., Ziegler D. Epidemiology of diabetic neuropathy. In: Gries F.A., Cameron N.E., Low P.A., Ziegler D. (eds.) New York: Textbook of Diabetic Neuropathy, 2003. Pp. 64–82.Shaw J.E., Zimmet P.Z., Gries F.A., Ziegler D. Epidemiology of diabetic neuropathy. In: Gries F.A., Cameron N.E., Low P.A., Ziegler D. (eds.) New York: Textbook of Diabetic Neuropathy, 2003. Pp. 64–82.19. Vinik A.I., Maser R.E., Mitchell B.D., Freeman R. Diabetic autonomic neuropathy. Diabetes Care 2003;26(5):1553–79.Vinik A.I., Maser R.E., Mitchell B.D., Freeman R. Diabetic autonomic neuropathy. Diabetes Care 2003;26(5):1553–79.20. Said G., Baudoin D., Toyooka K. Sensory loss, pains, motor deficit and axonal regeneration in length-dependent diabetic polyneuropathy. J Neurol 2008;255(11):1693–702.Said G., Baudoin D., Toyooka K. Sensory loss, pains, motor deficit and axonal regeneration in length-dependent diabetic polyneuropathy. J Neurol 2008;255(11):1693–702.21. Androne L., Gavan N.A., Veresiu I.A., Orasan R. In vivo effect of lipoic acid on lipid peroxidation in patients with diabetic neuropathy. In Vivo 2000;14(2):327–30.Androne L., Gavan N.A., Veresiu I.A., Orasan R. In vivo effect of lipoic acid on lipid peroxidation in patients with diabetic neuropathy. In Vivo 2000;14(2):327–30.22. Han D., Handelman G., Marcocci L. et al. Lipoic acid increases de novo synthesis of cellular glutathione by improving cystine utilization. Biofactors 1997;6(3):321–38.Han D., Handelman G., Marcocci L. et al. Lipoic acid increases de novo synthesis of cellular glutathione by improving cystine utilization. Biofactors 1997;6(3):321–38.23. Ziegler D. Thioctic acid for patients with symptomatic diabetic neuropathy: a critical review. Treat Endocrinol 2004;3(3):173–89.Ziegler D. Thioctic acid for patients with symptomatic diabetic neuropathy: a critical review. Treat Endocrinol 2004;3(3):173–89.24. Heitzer T., Finckh B., Albers S. et al. Beneficial effects of alpha-lipoic acid and ascorbic acid on endothelium-dependent, nitric oxide-mediated vasodilation in diabetic patients: relation to parameters of oxidative stress. Free Radic Biol Med 2001;31(1):53–61.Heitzer T., Finckh B., Albers S. et al. Beneficial effects of alpha-lipoic acid and ascorbic acid on endothelium-dependent, nitric oxide-mediated vasodilation in diabetic patients: relation to parameters of oxidative stress. Free Radic Biol Med 2001;31(1):53–61.25. Kishi Y., Schmelzer J.D., Yao J.K. et al. Alpha-lipoic acid: effect on glucose uptake, sorbitol pathway, and energy metabolism in experimental diabetic neuropathy. Diabetes 1999;48(10):2045–51.Kishi Y., Schmelzer J.D., Yao J.K. et al. Alpha-lipoic acid: effect on glucose uptake, sorbitol pathway, and energy metabolism in experimental diabetic neuropathy. Diabetes 1999;48(10):2045–51.26. Reljanovic M., Reichel G., Rett K. et al. Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Alpha Lipoic Acid in Diabetic Neuropathy. Free Radic Res 1999;31(3):171–9.Reljanovic M., Reichel G., Rett K. et al. Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Alpha Lipoic Acid in Diabetic Neuropathy. Free Radic Res 1999;31(3):171–9.27. Ziegler D., Hanefeld M., Ruhnau R.J. et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alphalipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study).Ziegler D., Hanefeld M., Ruhnau R.J. et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alphalipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study).ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy. Diabetes Care 1999;22(8):1296–301.28. Ametov A.S., Barinov A., Dyck P.J. et al. The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: the SYDNEY trial. Diabetes Care 2003;26(3):770–6.Ametov A.S., Barinov A., Dyck P.J. et al. The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: the SYDNEY trial. Diabetes Care 2003;26(3):770–6.29. Ziegler D., Ametov A., Barinov A. et al. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy. The SYDNEY 2 trial. Diabetes Care 2006;29(11):2365–70.Ziegler D., Ametov A., Barinov A. et al. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy. The SYDNEY 2 trial. Diabetes Care 2006;29(11):2365–70.30. Ziegler D., Nowak H., Kempler P. et al. Trea acid: a meta-analysis. Diabet Med 2004;21(2):114–21.Ziegler D., Nowak H., Kempler P. et al. Trea acid: a meta-analysis. Diabet Med 2004;21(2):114–21.31. Low P.A., Benrud-Larsen L.M., Sletten D.M. et al. Autonomic symptoms and diabetic neuropathy: a population-based study. Diabetes Care 2004;27(12):2942–7.Low P.A., Benrud-Larsen L.M., Sletten D.M. et al. Autonomic symptoms and diabetic neuropathy: a population-based study. Diabetes Care 2004;27(12):2942–7.